Login to Your Account



Amicus word due in three months

Actelion redux? Fabry bid enters phase III as Idorsia working with full pipeline

By Randy Osborne
Staff Writer

Thursday, May 17, 2018

With the countdown continuing to the Aug. 13 PDUFA date for Amicus Therapeutics Inc.'s migalastat in Fabry disease, Idorsia Ltd. has enrolled its first patient in a phase III registration study investigating the oral monotherapy lucerastat in that indication as well.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription